Exploring the best treatment options for BRAF-mutant metastatic colon cancer.

Finally, in a randomised phase 3 trial comparing bevacizumab plus FOLFIRI to bevacizumab plus FOLFOXIRI in mCRC patients, the subgroup of BRAF -mt patients appeared to benefit from the addition of oxaliplatin in terms of OS [19 versus 10.7 months; HR, 0.54 (95% CI, 0.24–1.20)], and PFS [7.5 versus 5.5 months; HR, 0.57 (95% CI, 0.27–1.23)], although this survival benefit did not reach statistical significance. 22 , 31 These results led to the recommendation of this upfront, aggressive schedule in patients with BRAF -mt mCRC in most recent guidelines. 2 , 33 , 34 However, it is important to emphasise that this ‘standard treatment’ is based on the observation of fewer than 100 patients in three studies.

also in 111,027 other papers